Hepatotoxicity of antibiotics. A review and update for the clinician.

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 609-642

  Stine, Jonathan G ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Drug safety; Drug induced liver injury; Monitoring

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CARBENICILLIN; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; CLOXACILLIN; DICLOXACILLIN; ERYTHROMYCIN ESTOLATE; ISONIAZID; MACROLIDE; MINOCYCLINE; NORFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TROLEANDOMYCIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; ACUTE CHOLECYSTITIS; ACUTE LIVER FAILURE; ARTIFICIAL VENTILATION; ASCITES; BACTERIAL SINUSITIS; BRONCHITIS; CHOLESTASIS; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EOSINOPHILIA; FEVER; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GRANULOMATOUS HEPATITIS; HLA SYSTEM; HUMAN; INTRAHEPATIC CHOLESTASIS; JAUNDICE; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER NECROSIS; LIVER TRANSPLANTATION; MORBIDITY; NAUSEA AND VOMITING; PANCREATITIS; PHARMACOGENOMICS; POSTOPERATIVE COMPLICATION; REGISTER; REVIEW; RISK FACTOR; SEPSIS; STEATOSIS; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS; DRUG SAFETY; DRUG-INDUCED LIVER INJURY; MONITORING;

ANTI-INFECTIVE AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 84884974812     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.008     Document Type: Review

References (265)

1. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott Williams and Wilkins, Philadelphia. 2nd edition.
2. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. JAntimicrob Chemother 2011, 66(7):1431-1446.
3. Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005, 42:481-489.
4. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 instances submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005, 129:512-521.
5. Reuben A., Koch D.G., Lee W.M. Acute liver failure study group. drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52(6):2065-2076. 10.1002/hep.23937.
6. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009, 15(7):719-729. [Erratum in Liver Transpl 2010;16(12):1446].
7. Devarbhavi H., Dierkhising R., Kremers W.K., et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010, 105(11):2396-2404.
8. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135(6):1924-1934.
9. De Valle M.B., Av Klinteberg V., Alem N., et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006, 24(8):1187-1195.
10. Reau N.S., Jensen D.M. Vanishing bile duct system. Clin Liver Dis 2008, 12(1):203-217.
11. Talwani R., Gilliam B.L., Howell C. Infectious diseases and the liver. Clin Liver Dis 2011, 15(1):111-130.
12. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to abacavir. NEngl J Med 2008, 358(6):568-579.
13. Daly A.K. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 2012, 52:21-35.
14. Daly A.K., Donaldson P.T., Bhatnagar P. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
15. Phillips E., Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009, 13(1):1-9.
16. Krawczyk M., Mullenbach R., Weber S., et al. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010, 7(12):669-681.
17. Suzuki A., Andrade R.J., Bjornsson E., et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010, 33(6):503-522.
18. Cunha B.A. Systemic infections affecting the liver. Some cause jaundice, some do not. Postgrad Med 1988, 84(5):161-163.
19. Shahian M., Rashtian P., Kalani M. Unexplained neonatal jaundice as an early diagnostic sign of urinary tract infection. Int J Infect Dis 2012, 16(7):e487-e490.
20. Kobashi H., Toshimori J., Yamamoto K. Sepsis-associated liver injury: incidence, classification and the clinical significance. Hepatol Res 2013, 43(3):255-266.
21. Brienza N., Dalfino L., Cinnella G., et al. Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 2006, 32(2):267-274.
22. Koskinas J., Gomatos I.P., Tiniakos D.G., et al. Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J Gastroenterol 2008, 14(9):1389-1393.
23. Tugwell P., Williams A.O. Jaundice associated with lobar pneumonia. A clinical, laboratory and histological study. QJ Med 1977, 46(181):97-118.
24. Ahmed A., Ahmed B. Jaundice in typhoid patients: differentiation from other common causes of fever and jaundice in the tropics. Ann Afr Med 2010, 9(3):135-140.
25. Datta S., Sarkar R.N., Biswas A., et al. Leptospirosis: an institutional experience. JIndian Med Assoc 2011, 109(10):737-738.
26. Taylor T.H., Lewis J.H. Tuberculosis of the liver, biliary tract and pancreas. Tuberculosis and nontuberculosis mycobacterial infections 2011, 373-408. ASM Press, Washington, DC. 6th edition. D. Schlossberg (Ed.).
27. Sembera S., Lammert C., Talwalkar J.A., et al. Frequency, clinical presentation and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl 2012, 18(7):803-810.
28. Zhenglu W., Hui L., Shuying Z.H., et al. Aclinical-pathological analysis of drug-induced hepatic injury after liver transplantation. Transplant Proc 2007, 39:3287-3291.
29. Faust T.W., Reddy K.R. Postoperative jaundice. Clin Liver Dis 2004, 8(1):151-166.
30. Chen E.Y., Baum K., Collins W., et al. Hepatitis E masquerading as drug-induced liver injury. Hepatology 2012, 56(6):2420-2423.
31. Davern T.J., Chalasani N., Fontana R.J., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141(5):1665-1672.
32. Dalton H.R., Fellows H.J., Stableforth W., et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007, 26(10):1429-1435.
33. Lucena M.I., Molokhia M., Shen Y., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141(1):338-347.
34. Donaldson P.T., Daly A.K., Henderson J., et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. JHepatol 2010, 53(6):1049-1053.
35. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012, 44(1):116-126.
36. Lee S.W., Chung L.S., Huang H.H., et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010, 14(5):622-626.
37. Tang S.W., Lv X.Z., Zhang Y., et al. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. JClin Pharm Ther 2012, 37(5):588-593.
38. An H.R., Wu X.Q., Wang Z.Y., et al. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 2012, 39(6):535-543.
39. Teixeira R.L., Morato R.G., Cabello P.H., et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011, 106(6):716-724.
40. Hawkins M.T., Lewis J.H. Latest advances in predicting DILI in humans: focus on biomarkers. Expert Opin Drug Metab Toxicol 2012, 8(12):1521-1530.
41. Cosgrove B., Alexopoulos L., Hang T. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol Biosyst 2010, 6:1195-1206.
42. Bell L., Vuppalanchi R., Watkins P. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 2012, 35:600-612.
43. Kim S.H., Kim S.H., Lee J.H., et al. Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs. Tuberculosis (Edinb) 2012, 92(1):100-104.
44. Wang T., Wang W., Wang Z.Y., et al. Association of P450-2E1 and GSTM1 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity. Zhonghua Jie He He Hu Xi Za Zhi 2009, 32(8):585-587. [in Chinese].
45. Chang J.C., Liu E.H., Lee C.N., et al. UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Int J Tuberc Lung Dis 2012, 16(3):376-378.
46. Li F., Lu J., Cheng J., et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 2013, 19(4):418-420.
47. Andrews E., Armstrong M., Tugwood J., et al. Arole for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010, 51(5):1656-1664.
48. Phillips E.J., Mallal S.A. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. AIDS 2013, 27(3):491-492.
49. Monshi M., Faulkner L., Gibson A., et al. HLA-B*57:01-restricted activation of drug-specific T-cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013, 57(2):727-739.
50. Bhadauria S., Mishra R., Kanchan R., et al. Isoniazid-induced apoptosis in HepG2 cells: generation of oxidative stress and Bcl-2 down-regulation. Toxicol Mech Methods 2010, 20(5):242-251.
51. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009, 29:400-411.
52. Hsiao C.J., Younis H., Boelsterli U.A. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem Biol Interact 2010, 188(1):204-213.
53. Goldstein L.I., Ishak K.G. Hepatic injury associated with penicillin therapy. Arch Pathol 1974, 98:114-117.
54. Onate J., Monejo M., Aguirrebenogoa K., et al. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis 1995, 20:474-475.
55. Williams C.N., Malatjalian D.A. Severe penicillin-induced cholestasis in a 91 year old woman. Dig Dis Sci 1981, 26:470-473.
56. Dismukes W.E. Oxacillin-induced hepatic dysfunction. JAMA 1973, 226:881-883.
57. Knirsch A.K., Gralla E.J. Abnormal serum transaminase levels after parenteral ampicillin and carbenicillin administration. NEngl J med 1970, 282:1081-1082.
58. Wilson F.M., Belamaric J., Lauter C.B., et al. Anicteric carbenicillin hepatitis. Eight episodes in four patients. JAMA 1975, 232:818-821.
59. Bengtsson F., Floren C.H., Hagerstrand I., et al. Flucloxacillin-induced cholestatic liver damage. Scand J Infect Dis 1985, 17:125-128.
60. Kleinman M.S., Presberg J.E. Cholestatic hepatitis after dicloxacillin-sodium therapy. JClin Gastroenterol 1986, 8:77-78.
61. Victorino R.M., Maria V.A., Correia A.P., et al. Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. Arch Intern Med 1987, 147:987-989.
62. Derby L.E., Jick H., Henry D.A., et al. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993, 158:596-600.
63. Miros M., Kerlin P., Walker N., et al. Flucloxacillin induced delayed cholestatic hepatitis. Aust N Z J Med 1990, 20:251-253.
64. Turner I.B., Eckstein R.P., Riley J.W., et al. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989, 151(11-12):701-705.
65. Lucena M.I., Andrade R.J., Kaplowitz N., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009, 49(6):2001-2009.
66. O'Donohue J., Oien K.A., Donaldson P., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000, 47:717-720.
67. Garcia Rodriguez L.A., Stricker B.H., Zimmerman H.J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996, 156:1327-1332.
68. Mari J.Y., Guy C., Beyens M.N., et al. Delayed drug-induced hepatic injury. Evoking the role of amoxicillin-clavulanic acid combination. Therapie 2000, 55:699-704. [in French].
69. Hautekeete M.L., Brenard R., Horsmans Y., et al. Liver injury related to amoxicillin-clavulanic acid: interlobular bile duct lesions and extrahepatic manifestations. JHepatol 1995, 22:71-77.
70. Caballero Plasencia A.M., Valenzuela Barranco M., Martin Ruiz J.L., et al. Hepatotoxicity caused by amoxicillin, clavulanic acid or both?. Gastroenterol Hepatol 1997, 20:45-46. [in Spanish].
71. Sweet J.M., Jones M.P. Intrahepatic cholestasis due to ticarcillin-clavulanate. Am J Gastroenterol 1995, 90:675-676.
72. Silvain C., Fort E., Levillain P., et al. Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. Dig Dis Sci 1992, 37:150-152. 596.
73. Bor O., Dinleyici E.C., Kebapci M., et al. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int 2004, 46:322-324.
74. Bickford C.L., Spencer A.P. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy 2005, 25:1389-1395.
75. Coleman C.I., Spencer J.V., Chung J.O., et al. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002, 36(7-8):1162-1167.
76. Henann N.E., Zambie M.F. Gatifloxacin-associated acute hepatitis. Pharmacotherapy 2001, 21:1579-1582.
77. Cheung O., Chopra K., Yu T., et al. Gatifloxacin-induced hepatotoxicity and acute pancreatitis. Ann Intern Med 2004, 140:73-74.
78. Bjornsson E., Olsson R., Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. Am J Gastroenterol 2000, 95:3662-3664.
79. Bataille L., Rahier J., Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. JHepatol 2002, 37:696-699.
80. Lazarczyk D.A., Goldstein N.S., Gordon S.C. Trovafloxacin hepatotoxicity. Dig Dis Sci 2001, 46:925-926.
81. Lucena M.I., Andrade R.J., Rodrigo L., et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000, 30:400-401.
82. Garey K.W., Amsden G.W. Trovafloxacin: an overview. Pharmacotherapy 1999, 19:21-34.
83. Chen H.J., Bloch K.J., MacLean J.A. Acute eosinophilic hepatitis from trovafloxacin. NEngl J Med 2000, 342:359-360.
84. Blum M.D., Graham D.J., McCloskey C.A. Temafloxacin syndrome: review of 95cases. Clin Infect Dis 1994, 18:946-950.
85. Ball P., Mandell L., Niki Y., et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999, 21:407-421.
86. Gonzalez Carro P., Huidobro M.L., Zabala A.P., et al. Fatal subfulminant hepatic failure with ofloxacin. Am J Gastroenterol 2000, 95:1606.
87. Azinge N.O., Garrick G.A. Stevens-Johnson syndrome (erythema multiforme) following ingestion of trimethoprim-sulfamethoxazole on two separate occasions in the same person: a case report. JAllergy Clin Immunol 1978, 62:125-126.
88. Dujovne C.A., Chan C.H., Zimmerman H.J. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. NEngl J Med 1967, 277:785-788.
89. Mainra R.R., Card S.E. Trimethoprim-sulfamethoxazole-associated hepatotoxicity - part of a hypersensitivity syndrome. Can J Clin Pharmacol 2003, 10:175-178.
90. Farrell J., Naisbitt D.J., Drummond N.S., et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. JPharmacol Exp Ther 2003, 306:229-237.
91. Naisbitt D.J., Gordon S.F., Pirmohamed M., et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation invivo. Br J Pharmacol 2001, 133:295-305.
92. Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol 1994, 89:789-791.
93. Zaman F., Ye G., Abreo K.D., et al. Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. Clin Transplant 2003, 17:461-464.
94. Munoz S.J., Martinez-Hernandez A., Maddrey W.C. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990, 12:342-347.
95. Carson J.L., Strom B.L., Duff A., et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993, 119(Pt 1):576-583.
96. Brett A.S., Shaw S.V. Simultaneous pancreatitis and hepatitis associated with trimethoprim-sulfamethoxazole. Am J Gastroenterol 1999, 94:267-268.
97. Lewis J.H., Zimmerman H.J. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999, 3:433-464.
98. Mohi-ud-din R., Lewis J.H. Drug- and chemical-induced cholestasis. Clin Liver Dis 2004, 8:95-132.
99. Yao F., Behling C.A., Saab S., et al. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997, 92:167-169.
100. Kowdley K.V., Keeffe E.B., Fawaz K.A. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 1992, 102:2148-2150.
101. Tanner A.R. Hepatic cholestasis induced by trimethoprim. Br Med J (Clin Res Ed) 1986, 293:1072-1073.
102. van der Ven A.J., Vree T.B., Koopmans P.P., et al. Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. JAntimicrob Chemother 1996, 37(Suppl B):55-60.
103. Johnson D.A., Cattau E.L., Kuritsky J.N., et al. Liver involvement in the sulfone syndrome. Arch Intern Med 1986, 146:875-877.
104. Sheen Y.S., Chu C.Y., Wang S.H., et al. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. JDermatolog Treat 2009, 20:340-343.
105. Agrawal S., Agarwalla A. Dapsone hypersensitivity syndrome: a clinicoepidemiological review. JDermatol 2005, 32:883-889.
106. Kunelis C.T., Peters J.L., Edmondson H.A. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 1965, 38:359-377.
107. Combes B., Whalley P.J., Adams R.H. Tetracycline and the liver. Prog Liver Dis 1972, 4:589-596.
108. Breen K., Schenker S., Heimberg M. The effect of tetracycline on the hepatic secretion of triglyceride. Biochim Biophys Acta 1972, 270:74-80.
109. Peters R.L., Edmondson H.A., Mikkelsen W.P., et al. Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases. Am J Surg 1967, 113:622-632.
110. Lewis J.H., Kleiner D.E. Hepatic injury due to drugs, herbal compounds, chemicals and toxins. MacSween's pathology of the liver 2012, 645-760. Churchill Livingstone Elsevier, Edinburgh (United Kingdom). 6th edition. A.D. Burt, B.C. Portmann, L.D. Ferrell (Eds.).
111. Freneaux E., Labbe G., Letteron P., et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988, 8:1056-1062.
112. Hunt C.M., Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994, 107:1844-1847.
113. Gough A., Chapman S., Wagstaff K., et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J 1996, 312:169-172.
114. Knowles S.R., Shapiro L., Shear N.H. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996, 132:934-939.
115. Lawrenson R.A., Seaman H.E., Sundstrom A., et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000, 23:333-349.
116. Cjara A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56(4):958-976.
117. Diehl A.M., Latham P., Boitnott J.K., et al. Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases. Am J Med 1984, 76:931-934.
118. Hosker J.P., Jewell D.P. Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP. Postgrad Med J 1983, 59:514-515.
119. Inman W.H., Rawson N.S. Erythromycin estolate and jaundice. Br Med J (Clin Res Ed) 1983, 286:1954-1955.
120. Zafrani E.S., Ishak K.G., Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979, 24:385-396.
121. Gholson C.F., Warren G.H. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990, 150:215-216.
122. Degott C., Feldmann G., Larrey D., et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992, 15:244-251.
123. Trauner M., Meier P.J., Boyer J.L. Molecular pathogenesis of cholestasis. NEngl J Med 1998, 339(17):1217-1227.
124. Chandrupatla S., Demetris A.J., Rabinovitz M. Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002, 47:2186-2188.
125. Suriawinata A., Min A.D. A33-year-old woman with jaundice after azithromycin use. Semin Liver Dis 2002, 22:207-210.
126. Pedersen F.M., Bathum L., Fenger C. Acute hepatitis and roxithromycin. Lancet 1993, 341:251-252.
127. Wallace R.J., Brown B.A., Griffith D.E. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993, 16:215-221.
128. Zimmerman H.J. Intrahepatic cholestasis. Arch Intern Med 1979, 139:1038-1045.
129. Haber I., Hubens H. Cholestatic jaundice after triacetyloleandomycin and oral contraceptives. The diagnostic value of gamma-glutamyl transpeptidase. Acta Gastroenterol Belg 1980, 43(11-12):475-482.
130. Spiers K.M., Zervos M.J. Telithromycin. Expert Rev Anti Infect Ther 2004, 2:685-693.
131. Clay K.D., Hanson J.S., Pope S.D., et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006, 144(6):415-420.
132. Chen Y., Guo J.J., Healy D.P., et al. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Ann Pharmacother 2008, 42(12):1791-1796.
133. Dore D.D., DiBello J.R., Lapane K.L. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf 2007, 30(8):697-703.
134. Brinker A.D., Wassel R.T., Lyndly J., et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009, 49(1):250-257.
135. Gleason P.P., Walters C., Heaton A.H., et al. Telithromycin:the perils of hasty adoption and persistence of off-label prescribing. JManag Care Pharm 2007, 13(5):420-425.
136. Goldstein L.I., Ishak K.G., Burns W. Hepatic injury associated with nitrofurantoin therapy. Am J Dig Dis 1974, 19:987-998.
137. Sharp J.R., Ishak K.G., Zimmerman H.J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980, 92:14-19.
138. Amit G., Cohen P., Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002, 4:184-186.
139. Sippel P.J., Agger W.A. Nitrofurantoin-induced granulomatous hepatitis. Urology 1981, 18:177-178.
140. Koulaouzidis A., Bhat S., Moschos J., et al. Nitrofurantoin-induced lung- and hepatotoxicity. Ann Hepatol 2007, 6:119-121.
141. Feder H. Chloramphenicol: what we have learned in the last decade. South Med J 1986, 79(9):1129-1134.
142. Fernandez-Villar A., Sopena B., Fernandez-Villar J., et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004, 8:1499-1505.
143. McNeill L., Allen M., Estrada C., et al. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003, 123:102-106.
144. Scheuer P.J., Summerfield J.A., Lal S., et al. Rifampicin hepatitis. A clinical and histological study. Lancet 1974, 1:421-425.
145. Fountain F.F., Tolley E.A., Jacobs A.R., et al. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection. Am J Med Sci 2009, 337(5):317-320. 10.1097/MAJ.0b013e31818c0134.
146. Stout J.E. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opin Drug Saf 2004, 3(3):187-198.
147. Sochocky S. Acute hepatitis due to para-aminosalicylic acid. Br J Clin Pract 1971, 25:179-182.
148. Gulliford M., Mackay A.D., Prowse K. Cholestatic jaundice caused by ethambutol. Br Med J (Clin Res Ed) 1986, 292:866.
149. Chong V.H., Lim K.S. Hepatobiliary tuberculosis. Singapore Med J 2010, 51(9):744-751.
150. Amarapurkar D.N., Patel N.D., Amarapurkar A.D. Hepatobiliary tuberculosis in western India. Indian J Pathol Microbiol 2008, 51(2):175-181.
151. Mitchell J.R., Zimmerman H.J., Ishak K.G., et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976, 84(2):181-192.
152. Byrd R.B., Horn B.R., Solomon D.A., et al. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA 1979, 241(12):1239-1241.
153. Garibaldi R.A., Drusin R.E., Ferebee S.H., et al. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972, 106:357-365.
154. Black M., Mitchell J.R., Zimmerman H.J., et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975, 69:289-302.
155. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281:1014-1018.
156. Fountain F.F., Tolley E., Chrisman C.R., et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005, 128(1):116-123.
157. Scharer L., Smith J.P. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969, 71:1113-1120.
158. Lewis J.H. The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y) 2012, 8(5):333-336.
159. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
160. Huang Y.S., Chern H.D., Su W.J., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35:883-889.
161. Gao X.F., Wang L., Liu G.J., et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006, 10(10):1080-1090.
162. Akolo C., Adetifa I., Shepperd S., et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, (1). CD000171. 10.1002/14651858.CD000171.pub3.
163. Metushi I.G., Cai P., Zhu X., et al. Afresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011, 89(6):911-914.
164. Durand F., Jebrak G., Pessayre D., et al. Hepatotoxicity of antitubercular treatments. Rational for monitoring liver status. Drug Saf 1996, 15(6):394-405.
165. American Thoracic Society/CDC Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:735-739.
166. Steele M.A., Burk R.F., DesPrez R.M. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991, 99:465-471.
167. Pessayre D. Present views on isoniazid and isoniazid-rifampicin hepatitis. Agressologie 1982, 23:13-15.
168. Rae J.M., Johnson M.D., Lippman M.E., et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression assays. JPharmacol Exp Ther 2001, 229:849-857.
169. Gordin F.M., Cohn D.L., Matts J.P., et al. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?. Clin Infect Dis 2004, 39(4):561-565.
170. Byrne J.A., Strautnieks S.S., Mieli-Vergani G., et al. The human bile salt export pump: characteristics of substrate specificity and identification of inhibitors. Gastroenterology 2002, 123:1649-1658.
171. Capelle P., Dhumeaux D., Mora M., et al. Effect of rifampicin on liver function in man. Gut 1972, 13:366-371.
172. Grosset J., Leventis S. Adverse effects of rifampicin. Rev Infect Dis 1983, 5:S440-S450.
173. Benson C.A., Williams P.L., Cohn D.L., et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Reasearch on AIDS 009 Protocol Team. JInfect Dis 2000, 181(4):1289-1297.
174. Aristoff P.A., Garcia G.A., Kirchhoff P.D. Hollis Showalter HD. Rifamycins-obstacles and opportunities. Tuberculosis (Edinb) 2010, 90(2):94-118.
175. Chang K.C., Leung C.C., Yew W.W., et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008, 177:1391-1396.
176. Khokhar O., Gange C., Clement S., et al. Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci 2005, 50:207-211.
177. Lacroix C., Guyonnaud C., Chaou M., et al. Interactions between allopurinol and pyrazinamide. Eur Respir J 1988, 1:807-811.
178. Tostmann A., Aamoutse R.E., Peters W.H., et al. Xanthine oxidase inhibition by allopurinol increases invitro pyrazinamide-induced hepatotoxicity in HepG2 cells. Drug Chem Toxicol 2010, 33(3):325-328.
179. Shih T.Y., Pai C.Y., Yang P., et al. Anovel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother 2013, 57(4):1685-1690. 10.1128/AAC.01866-12.
180. Prasad R., Verma S.K., Sahai S., et al. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci 2006, 48(3):183-186.
181. Saukkonen J.J., Cohn D.L., Jasmer R.M., ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
182. Centers for Disease Control and Prevention Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection -- United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010, 59(8):224-229.
183. Kunst H., Khan K.S. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010, 14(11):1374-1381.
184. Franks A.L., Binkin N.J., Snider D.E., et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989, 104(2):151-155.
185. Sharma S.K., Singla R., Sarda P., et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010, 50(6):833-839.
186. Singla R., Sharma S.K., Mohan A., et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010, 132:81-86.
187. Warmelink I., Ten Hacken N.H., van der Werf T.S., et al. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 2010, 28:1-9.
188. Pasipanodya J.G., Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother 2010, 54(7):2847-2854.
189. Ungo J.R., Jones D., Ashkin D., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1871-1876.
190. Nader L.A., de Mattos A.A., Picon P.D., et al. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?. Ann Hepatol 2010, 9(1):70-74.
191. Sirinak C., Kittikraisak W., Pinjeesekikul D., et al. Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health 2008, 8:245.
192. Huang Y.S., Chern H.D., Su W.J., et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003, 37(4):924-930.
193. Tang N., Deng R., Wang Y., et al. GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2013, 17(1):17-25. 10.5588/ijtld.12.0447.
194. Forestiero F.J., Cecon L., Hirata M.H., et al. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clin Chim Acta 2013, 415:215-219. 10.1016/j.cca.2012.10.030.
195. Tang S.W., Lv X.Z., Chen R., et al. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9, CYP2C19 and anti-tuberculosis drug-induced liver injury in community-based Chinese population. Clin Exp Pharmacol Physiol 2013, 40(5):326-332. 10.1111/1440-1681.12074.
196. Azuma J., Ohno M., Kubota R., et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013, 69(5):1091-1101.
197. Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010, 50(6):840-842.
198. Senousy B.E., Belal S.I., Draganov P.V. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol 2010, 7(10):543-556.
199. Ichai P., Saliba F., Antoun F., et al. Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. Liver Transpl 2010, 16(10):1136-1146.
200. Baniasadi S., Eftekhari P., Tabarsi P., et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010, 22(10):1235-1238.
201. Li J., Lin W.F., Pan Y.Y., et al. Protective effect of silibinin on liver injury induced by antituberculosis drugs. Zhonghua Gan Zang Bing Za Zhi 2010, 18(5):385-386. [in Chinese].
202. Yue J., Dong G., He C., et al. Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. Toxicology 2009, 264(3):185-191.
203. Singh M., Sasi P., Gupta V.H., et al. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an invitro model. Hum Exp Toxicol 2012, 31(8):788-797.
204. Samuel A.J., Mohan S., Chellappan D.K., et al. Hibiscus vitifolius (Linn) root extract shows potent protective action against anti-tubercular drug induced hepatotoxicity. JEthnopharmacol 2012, 141(1):396-402.
205. Jafri S.M., Singal A.G., Kaul D., et al. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl 2011, 17(3):306-314.
206. Fábrega E., Sampedro B., Cabezas J., et al. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transpl 2012, 18(9):1110-1117.
207. Stucchi R.S., Boin I.F., Angerami R.N., et al. Is isoniazid safe for liver transplant candidates with latent tuberculosis?. Transplant Proc 2012, 44(8):2406-2410.
208. Yehia B.R., Blumberg E.A. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl 2010, 16(10):1129-1135.
209. Bodro M., Sabé N., Santín M., et al. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Transplant Proc 2012, 44(9):2686-2689.
210. Lewis J.H., Zimmerman H.J., Benson G.D., et al. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984, 86:503-513.
211. Lake-Bakaar G., Scheuer P.J., Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987, 294:419-422.
212. Stricker B.H., Blok A.P., Bronkhorst F.B., et al. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. JHepatol 1986, 3:399-406.
213. Bronstein J.A., Gros P., Hernandez E., et al. Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis 1997, 25:1266-1267.
214. Ikemoto H. Aclinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989, 12(Suppl 4):239S-247S.
215. Gupta A.K., Chwetzoff E., Del Rosso J., et al. Hepatic safety of itraconazole. JCutan Med Surg 2002, 6:210-213.
216. Talwalkar J.A., Soetikno R.E., Carr-Locke D.L., et al. Severe cholestasis related to itraconazole for the treatment of onychomycosis. Am J Gastroenterol 1999, 94:3632-3633.
217. Somchit N., Norshahida A.R., Hasiah A.H., et al. Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative invivo study. Hum Exp Toxicol 2004, 23:519-525.
218. Chu H.Y., Jain R., Xie H., et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 2013, 13(1):105.
219. Solís-Muñoz P., López J.C., Bernal W., et al. Voriconazole hepatotoxicity in severe liver dysfunction. JInfect 2013, 66(1):80-86.
220. Miller M.A. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984, 131:1245-1247.
221. Vermes A., Guchelaar H.J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. JAntimicrob Chemother 2000, 46:171-179.
222. Anania F.A., Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002, 112:741-742.
223. Fernandes N.F., Geller S.A., Fong T.L. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998, 93:459-460.
224. Lazaros G.A., Papatheodoridis G.V., Delladetsima J.K., et al. Terbinafine-induced cholestatic liver disease. JHepatol 1996, 24:753-756.
225. Lovell M.O., Speeg K.V., Havranek R.D., et al. Histologic changes resembling acute rejection in a liver transplant patient treated with terbinafine. Hum Pathol 2003, 34:187-189.
226. Ajit C., Suvannasankha A., Zaeri N., et al. Terbinafine-associated hepatotoxicity. Am J Med Sci 2003, 325:292-295.
227. Paredes A.H., Lewis J.H. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother 2007, 41(5):880-884.
228. Kleiner D.E., Gaffey M.J., Sallie R., et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997, 10:192-199.
229. Cervoni J.P., Degos F., Marcellin P., et al. Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. JHepatol 1997, 27:1113-1116.
230. Lock G., Reng C.M., Graeb C., et al. Interferon-induced hepatic failure in a patient with hepatitis C. Am J Gastroenterol 1999, 94:2570-2571.
231. Papo T., Marcellin P., Bernuau J., et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992, 116:51-53.
232. Veerabagu M.P., Finkelstein S.D., Rabinovitz M. Granulomatous hepatitis in a patient with chronic hepatitis C treated with interferon-alpha. Dig Dis Sci 1997, 42:1445-1448.
233. Goldin R.D., Levine T.S., Foster G.R., et al. Granulomas and hepatitis C. Histopathology 1996, 28:265-267.
234. Lewis J.H. Granulomas of the liver. Schiff's diseases of the liver 2011, 1034-1058. Lippincott Williams and Wilkins, Baltimore (MD). 11th edition. E.R. Schiff, M.F. Sorrell, W.C. Maddrey (Eds.).
235. Dousset B., Conti F., Houssin D., et al. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. NEngl J Med 1994, 330:1160-1161.
236. Janssen H.L., Brouwer J.T., Nevens F., et al. Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). Br Med J 1993, 306:107-108.
237. Cianciara J., Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig Dis Sci 1995, 40:1842-1844.
238. Bernuau J., Larrey D., Campillo B., et al. Amodiaquine-induced fulminant hepatitis. JHepatol 1988, 6:109-112.
239. Wharton J.M., Coleman D.L., Wofsy C.B., et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986, 105:37-44.
240. Bjornsson E., Nordlinder H., Olsson R. Metronidazole as a probable cause of severe liver injury. Hepatogastroenterology 2002, 49:252-254.
241. Farid Z., Smith J.H., Bassily S., et al. Hepatotoxicity after treatment of schistosomiasis with hycanthone. Br Med J 1972, 2:88-89.
242. Manivel J.C., Bloomer J.R., Snover D.C. Progressive bile duct injury after thiabendazole administration. Gastroenterology 1987, 93:245-249.
243. Roy M.A., Nugent F.W., Aretz H.T. Micronodular cirrhosis after thiabendazole. Dig Dis Sci 1989, 34:938-941.
244. Reshef R., Lok A.S., Sherlock S. Cholestatic jaundice in fascioliasis treated with niclofolan. Br Med J (Clin Res Ed) 1982, 285:1243-1244.
245. Hamlyn A.N., Morris J.S., Sarkany I., et al. Piperazine hepatitis. Gastroenterology 1976, 70:1144-1147.
246. Jagota S.C. Jaundice due to albendazole. Indian J Gastroenterol 1989, 8:58.
247. Junge U., Mohr W. Mebendazole-hepatitis. ZGastroenterol 1983, 21:736-738. [in German].
248. Ebeid F., Farghali H., Botros S., et al. Praziquantel did not exhibit hepatotoxicity ina study with isolated hepatocytes. Trans R Soc Trop Med Hyg 1990, 84(2):262-264.
249. Stine J.G., Lewis J.H. Review article: use of medications in patients with cirrhosis. Aliment Pharmacol Ther 2013, 37(12):1132-1156.
250. Segarra-Newnham M., Henneman A. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis in patients without gastrointestinal bleeding. Ann Pharmacother 2010, 44(12):1946-1954.
251. Chavez-Tapia N.C., Barrientos-Gutierrez T., Tellez-Avila F.I., et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010, (9). CD002907. 10.1002/14651858.CD002907.pub2.
252. Terg R., Fassio E., Guevara M., et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. JHepatol 2008, 48(5):774-779.
253. Dixit R.K., Satapathy S.K., Kumar R., et al. Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. Indian J Gastroenterol 2002, 21:62-63.
254. Montay G., Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. JAntimicrob Chemother 1990, 26(Suppl B):61-67.
255. Silvain C., Bouquet S., Breux J.P., et al. Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis. Eur J Clin Pharmacol 1989, 37(3):261-265.
256. Sambatakou H., Giamarellos-Bourboulis E.J., Galanakis N., et al. Phramacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascetic fluid. Int J Antimicrob Agents 2001, 18:441-444.
257. Vuppalanchi R., Juluri R., Ghabril M., et al. Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. JClin Gastroenterol 2011, 45(7):638-642.
258. Amarapurkar D.N. Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol 2011, 2011:1-5.
259. Cho Y.J., Lee S.M., Yoo C.G., et al. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology 2007, 12:401-405.
260. Gupta N.K., Lewis J.H. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008, 28:1021-1041.
261. Saito A., Nagayama N., Yagi O., et al. Tuberculosis complicated with liver cirrhosis. Kekkaku 2006, 81:457-465.
262. Jahng A.W., Tran T., Bui L., et al. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007, 83:1557-1562.
263. Holty J.E., Gould M.K., Meinke L., et al. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009, 15:894-906.
264. Kaneko Y., Nagayama N., Kawabe Y., et al. Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis. Kekkaku 2008, 83:13-19.
265. Park W.B., Kim W., Lee K.L., et al. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. JInfect 2010, 61(4):323-339.